ES2B-C001

About ExpreS2ion Biotechnologies

ExpreS2ion Biotechnologies is a clinical-stage biotech focused on developing transformative vaccines using its proprietary ExpreS2 protein expression platform. Founded in 2010 and publicly listed on Nasdaq First North Growth Market Sweden, the company has advanced its lead HER2-targeted cancer vaccine, ES2B-C001, into Phase 1 trials, demonstrating promising early immunogenicity. Its strategy leverages the ExpreS2 platform's ability to efficiently produce properly folded antigens to build a pipeline targeting high-need areas in oncology and infectious diseases.

Therapeutic Areas

Other HER2-positive cancers Drugs